A study comparing the use of two drugs, Granisetron and Ondansetron, for the prevention of nausea and vomiting after surgical procedures under general anaesthesia with inhalational anaesthetic drugs

A comparative study of intravenous Granisetron and Ondansetron for the prophylaxis of postoperative nausea and vomiting following surgical procedures under general anaesthesia using inhalational agents: A prospective randomized - NIL

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2022/03/040826

Enrollment

100

Registered

2022-03-04

Start date

Unknown

Completion date

Unknown

Last updated

2022-04-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K352- Acute appendicitis with generalized peritonitis Health Condition 2: D249- Benign neoplasm of unspecified breast Health Condition 3: K811- Chronic cholecystitis Health Condition 4: H701- Chronic mastoiditis Health Condition 5: K565- Intestinal adhesions [bands] withobstruction (postinfection)

Interventions

Intervention1: i.v. granisetron: Granisetron is a serotonin 5-HT3 receptor antagonist that is used as an antiemetic to treat nausea and vomiting after chemotherapy or radiotherapy. Its primary functio

Eligibility

Inclusion criteria

Inclusion criteria: -Age 18yrs â?? 50 yrs -ASA grades I and II -Weighing more than 40 kg, -Those scheduled under general anaesthesia using inhalational agents will be included in the study

Exclusion criteria

Exclusion criteria: a) Patients not giving consent b) ASA grades III and IV patients. c)Age 50yrs. d) Had taken antiemetic drugs within 24 hours before surgery. e)Emergency surgeries & Full stomach f)History of motion sickness or previous PONV g)Total intravenous anesthesia

Design outcomes

Primary

Measure	Time frame
To compare the efficacy & safety of granisetron i.v. vs standard of care ondansetron i.v. in patients undergoing surgery under general anaesthesia.Timepoint: First 24 hours, grouped as 0-1 hours,1-3 hours,3-6 hours,6-12 hours,12-24 hours post surgery	—

Secondary

Measure	Time frame
The effect of these drugs on clinical recovery, based on episodes of vomiting and recovery time. Nausea not considered as a symptom for the secondary outcome.Timepoint: first 24 hours, post surgery	—

Countries

India

Contacts

Public ContactShubhangee Tiwari

Peoples College of Medical Sciences & Research Centre, Bhanpur, Bhopal

drmahimabatra@gmail.com9752975418

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026